<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702568</url>
  </required_header>
  <id_info>
    <org_study_id>BCX9930-201</org_study_id>
    <secondary_id>2020-000501-93</secondary_id>
    <nct_id>NCT04702568</nct_id>
  </id_info>
  <brief_title>A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)</brief_title>
  <official_title>A Phase 2, Open-Label Study to Evaluate the Long-term Safety of Oral BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the long-term safety of daily oral treatment with BCX9930&#xD;
      in subjects who have participated in a previous BCX9930 trial for PNH and showed a benefit of&#xD;
      treatment as determined by the Investigator. The study allows continued access to BCX9930 for&#xD;
      enrolled subjects. The study will also evaluate the long-term effectiveness and impact on&#xD;
      quality of life and general well-being of BCX9930 treatment, and the subject's satisfaction&#xD;
      with the medication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 18, 2020</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of graded treatment-emergent adverse events</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of graded laboratory chemistry abnormalities</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of graded hematology abnormalities</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of graded coagulation abnormalities</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in temperature</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in respiratory rate</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Electrocardiogram (PR interval)</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Electrocardiogram (QT interval)</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Electrocardiogram (QRS interval)</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Electrocardiogram (RR interval)</measure>
    <time_frame>Week 50</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of blood transfusions</measure>
    <time_frame>Day 1 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase</measure>
    <time_frame>absolute and change from Day 1 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>absolute and change from Day 1 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute reticulocyte count</measure>
    <time_frame>absolute and change from Day 1 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haptoglobin</measure>
    <time_frame>absolute and change from Day 1 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical PNH symptom assessments</measure>
    <time_frame>absolute and change from Day 1 through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum AP complement activity</measure>
    <time_frame>change through Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Factor Bb</measure>
    <time_frame>change through Week 50</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>PNH</condition>
  <arm_group>
    <arm_group_label>BCX9930</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: BCX9930</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCX9930</intervention_name>
    <description>BCX9930 for oral administration</description>
    <arm_group_label>BCX9930</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female subjects&#xD;
&#xD;
          -  Successfully participated in a previous BCX9930 study of PNH and experienced&#xD;
             improvement in their PNH&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Apart from a diagnosis of PNH, any clinically significant medical or psychiatric&#xD;
             condition or medical history, other than those associated with PNH disease, that, in&#xD;
             the opinion of the Investigator or Sponsor, would interfere with the subject's ability&#xD;
             to participate in the study or participation would increase the risk for that subject&#xD;
&#xD;
          -  Pregnant, planning to become pregnant, or having been pregnant within 90 days of Day&#xD;
             1, or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morag Griffin, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds Teaching Hospitals NHS Trust, Leeds, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Center</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCX9930</keyword>
  <keyword>Factor D inhibitor</keyword>
  <keyword>PNH</keyword>
  <keyword>paroxysmal Nocturnal Hemoglobinuria</keyword>
  <keyword>oral treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

